4.6 Review

Anti-flavivirus Properties of Lipid-Lowering Drugs

期刊

FRONTIERS IN PHYSIOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2021.749770

关键词

lipids; flavivirus; antivirals; cholesterol; fatty acids; statins; metformin

资金

  1. National Council of Science and Technology of Mexico (CONACYT) [220824]
  2. CONACYT

向作者/读者索取更多资源

Host lipid metabolism plays a crucial role in controlling flavivirus infections, with FDA-approved hypolipidemic drugs potentially serving as alternative treatments. Further understanding of the regulation between host lipid metabolism and signaling pathways triggered during infections is needed to explore the potential of lipid-lowering drugs as safe host-targeted antivirals.
Although Flaviviruses such as dengue (DENV) and zika (ZIKV) virus are important human pathogens, an effective vaccine or antiviral treatment against them is not available. Hence, the search for new strategies to control flavivirus infections is essential. Several studies have shown that the host lipid metabolism could be an antiviral target because cholesterol and other lipids are required during the replicative cycle of different Flaviviridae family members. FDA-approved drugs with hypolipidemic effects could be an alternative for treating flavivirus infections. However, a better understanding of the regulation between host lipid metabolism and signaling pathways triggered during these infections is required. The metabolic pathways related to lipid metabolism modified during DENV and ZIKV infection are analyzed in this review. Additionally, the role of lipid-lowering drugs as safe host-targeted antivirals is discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据